Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study

Anticancer Research

Volumn 18, Issue 4 B, 1998, Pages 2779-2788

  Denardo, Gerald L ^a,d   Denardo, Sally J ^a   Kukis, David L ^a   O'Donnell, Robert T ^a   Shen, Sui ^a   Goldstein, Desiree S ^a   Kroger, Linda A ^a   Salako, Qansy ^a   Denardo, Diane A ^a   Mirick, Gary R ^a   Mausner, Leonard F ^b   Srivastava, Suresh C ^b   Meares, Claude F ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Molecular Cancer Institute   (United States)

Author keywords

Copper 67; Lymphoma; MTD; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; CERULOPLASMIN; COPPER 67; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; DOSIMETRY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TUMOR REGRESSION;

ADULT; ANTIBODIES, MONOCLONAL; CERULOPLASMIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COPPER RADIOISOTOPES; DOSE FRACTIONATION; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 14444270630     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. DeNardo SJ, DeNardo GL, O'Grady LF, Levy NB, Mills SL, Macey DJ, McGahan JP, Miller CH, Epstein AL: Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiophar 1: 17-33, 1988.
2. DeNardo SJ, DeNardo GL, O'Grady LF, Macey DJ, Mills SL, Epstein AL, Peng J-S, McGahan JP: Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers 2: 49-53, 1987.
3. 131I-Lym-1. Cancer Res 50 Suppl: 1014-1016, 1990.
4. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336-340, 1995.
5. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, et al: Iodine-131 -anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14: 1974-1981, 1996.
6. Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA: Phase 1 dose-escalation trial of iodine 131 -labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 11: 2021-2029, 1993.
7. 131I-labeled monoclonal antibody: an Illinois Cancer Council study. J Clin Oncol 5: 562-573, 1985.
8. Parker BA, Vassos AB, Halpern SE, Miller RA, Hups H, Amox BG, Simoni JL, Starr RJ, Green MR, Royston I: Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal antibody. Cancer Res 50: 1022-1028, 1990.
9. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, et al: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9: 548-564, 1991.
10. Vriesendorp HM, Herpst JM, Germack MA, Klein JL, Leichner PK, Loudenslager DM, Order SE: Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol 9: 918-928, 1991.
11. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, et al: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9: 478-490, 1991.
12. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF: Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73: 1425-1432, 1994.
13. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Cancer 80 Suppl: 2706-2711, 1997.
14. Stein R, Chen S, Haim S, Goldenberg DM: Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer 80: 2636-2641, 1997.
15. 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb351. Cancer Res 53: 5727-5733, 1993.
16. DeNardo GL, DeNardo SJ: Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer. In: Radioimmunoimaging and Radioimmunotherapy (Burchiel, SW, Rhodes, BA, eds). New York, Elsevier Science Publishing Co., Inc. 1983, PP 41-62.
17. Jungerman JA, Yu KH, Zanelli Cl: Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy. Int J Appl Radiat Isot 35: 883-888, 1984.
18. Linder MC, Hazegh-Azam M: Copper biochemistry and molecular biology. Am J Clin Nutr 63: 797S-811S, 1996.
19. Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ: Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 148: 249-253, 1985.
20. Kukis DL, Li M, Meares CF: The selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorganic Chemistry 32: 3981-3982,1993.
21. Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP, Meares CF: Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 55: 878-884, 1995.
22. Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, Salako QA, Meares CF: A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 73 Suppl: 779-786,1994.
23. DeNardo GL, DeNardo SJ, Lewis JP, Salako QA, Levy NB, Goldstein DS, McGahan JP, Lamborn KR: Maximum tolerated dose (MTD) of 1-131 Lym-1 in non-Hodgkin's lymphoma (NHL); responses and toxicities. J Clin Oncol 13: 368, 1994.
24. 67Cu-BAT-Lym-1 monoclonal antibody in patients with B cell lymphoma. J Nucl Med 32: 984, 1991.
25. DeNardo DA, DeNardo GL, Yuan A, Shen S, DeNardo SJ, Macey DJ, Lamborn KR, Mahe MA, Groch MW, Erwin WD: Prediction of radiation doses from therapy using tracer studies with lodine-131 labeled antibodies. J Nucl Med 37: 1970-1975, 1996.
26. DeNardo SJ, DeNardo GL, O'Grady LF, Hu E, Sytsma VM, Mills SL, Levy NB, Macey DJ, Miller CH, Epstein AL: Treatment of B cell malignancies with 1-131 Lym-1 monoclonal antibodies. Int J Cancer 3 Suppl: 96-101, 1988.
27. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the committee on Hodgkin's disease staging classification. Cancer Res 31: 1860-1861, 1971.
28. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49: 2112-2135, 1982.
29. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF: Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 43: 26-30, 1996.
30. Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen FM, Parker JW, Taylor CR: Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47: 830-840, 1987.
31. Hu E, Epstein AL, Naeve GS, Gill I, Martin S, Sherrod A, Nichols P, Chen D, Mazumder A, Levine AM: A phase 1 a clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7: 155-166, 1989.
32. McCall MJ, Diril H, Meares CF: Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug Chem 1: 222-226,1990.
33. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res 3: 71-79, 1997.
34. DeNardo GL, Kukis DL, Shen S, DeNardo SJ: Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator. J Nucl Med 37: 302-306, 1996.
35. WHO handbook for reporting results of cancer treatment. WHO Offset Publication 48: 1979.
36. DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ: Antibody responses to macrocycles in lymphoma. J Nucl Med 37: 451-456, 1996.
37. DeNardo GL, DeNardo SJ, Meares CF, Kukis DL, Diril H, McCall MJ, Adams GP, Mausner LF, Moody DC, Deshpande SV: Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and patients with lymphoma. Antibody Immunoconj Radiophar 4: 777-785, 1991.
38. Erwin WD, Groch MW, Macey DJ, DeNardo GL, DeNardo SJ, Shen S: A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol 23: 525-532, 1996.
39. Shen S, DeNardo GL, DeNardo SJ, Salako QA, Morris G, Banks D, Yuan A, DeNardo DA: Dosimetric evaluation of Cu-64 in Cu-67-2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl Med 37: 146-150, 1996.
40. Shen S, DeNardo GL, DeNardo SJ, Yuan A, DeNardo DA, Lamborn KR: Reproducibility of operator processing for radiation dosimetry. Nucl Med Biol 24: 77-83, 1997.
41. Loevinger R, Berman M: A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No.1. New York, Society of Nuclear Medicine, 1976.
42. Coffey JL, Watson EE: Calculating dose from remaining body activity: a comparison of two methods. Med Phys 6: 307-308, 1979.
43. Snyder WS, Ford MR, Warner GG, Watson SB: "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No.11. New York, Society of Nuclear Medicine, 1975.
44. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 14: 587-595, 1993.
45. Lim S-M, DeNardo GL, DeNardo DA, Shen S, Yuan A, O'Dopnell RT, DeNardo SJ: Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med 38: 1374-1378, 1997.
46. Jain RK: Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 60: 85-100, 1991.
47. Langmuir VK, McGann JK, Buchegger F, Sutherland RM: The effect of antigen concentration, antibody valency and size, and tumor architecture on antibody binding in multicell spheroids. Nucl Med Biol 18: 753-764, 1991.
48. Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russel C, Colcher D, Schlom J, Shochat D, LoBuglio AF: Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 33: 1648-1653, 1992.
49. Knox SJ, Levy R, Miller RA, Uhland W, Schiele J, Ruehl W, Finston R, Day-Lollini P, Goris ML: Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 50; 4935-4940, 1990.
50. Buchegger F, Vacca A, Carrel S, Schreyer M, Mach JP: Radioimmunotherapy of human colon carcinoma by 1311-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer 41: 127-134,1988.
51. Schlom J, Molinolo A, Simpson JF, Siler K, Roselli M, Hinkle G, Houchens DP, Colcher D: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82: 763-771, 1990.
52. Dillman RO: Magic bullets at last! Finally - approval of a monoclonal antibody for the treatment of cancer. Cancer Biotherapy and Radiopharmaceuticals 12: 223-225, 1997.
53. DeNardo GL, DeNardo SJ, Kukis DL, et al: Strategies for enhancement of radioimmunotherapy. Nucl Med Biol 18: 633-640. 1991.
54. DeNardo SJ, DeNardo GL: Tumor therapy with radioactive labeled antitumor antibodies. In: Cellular oncology: New approaches in biology, diagnosis and treatment (Moloy, PJ, Nicolson, G, eds). New York, Praeger Press, 1983, pp 282-292.
55. Wessels BW, Rogus RD: Radionuclide selection and model adsorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11: 638-645, 1984.
56. Delaloye AB, Delaloye B, Buchegger F, Vogel CA, Gillet M, Mach JP, Smith A, Schubiger PA: Comparison of copper-67-and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. J Nucl Med 58: 847-853, 1997.
57. 67Cu-2IT-BAT-Lym-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2. Cancer 80 Suppl: 2576-2582, 1997.
58. Philpott GW, Schwarz SW, Andersen CJ, Dehdashti F, Connett JM, Zinn KR, Meares CF, Cutler PD, Welch MJ, Siegel BA: RadioimmunoPET: detection of colorectal carcinoma with positronemitting copper-64-labeled monoclonal antibody. J Nucl Med 36: 1818-1824, 1995.
59. Anderson CJ, Connett JM, Schwarz SW, Rocque PA, Guo LW, Philpott GW, Zinn KR, Meares CF, Welch MJ: Copper-64-labeled antibodies for PET imaging. J Nucl Med 33: 1685-1691, 1992.
60. 67Cu. Int J Rad Appl Instrum [A] 37: 29-36, 1986.
61. Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA: Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 52: 904-911, 1992.
62. Dasgupta AK, Mausner LF, Srivastava SC: A new separation procedure for Cu-67 from proton irradiated Zn. J Appl Radiat Isot 42: 371-376, 1991.
63. Mausner LF, Srivastava SC: Selection of radionuclides for radioimmunotherapy. Med Phys 20: 503-509, 1993.
64. Srivastava SC: Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals 11: 43-50, 1996.
65. Harris ED: Copper transport: an overview. Proc Soc Exp Biol Med 196: 130-140, 1991.
66. Linder MC, Weiss KC, Vu HM, Ruclcer RB: Structure and function of transcuprein in transport of copper by mammalian blood plasma In: Trace elements in man and animals (TEMA-6) (Hurley, LC, Connerdal, B, Keen, C, eds). New Yorlc, Plenum Press, 1987, pp 141-144.
67. Luza SC, Speisky HC: Liver copper storage and transport during development: implications for cytot,oxicity. Am J Clin Nutr 63: 812S-20S, 1996.
68. 111In-and 90Y-DOTA-peptide in tumor bearing mice. J Nucl Med 36: 829-836, 1995.
69. Larson SM, Carrasquillo JA: Advantages of radioiodine over radioindium labeled monoclonal antibodies for imaging solid tumors. Nucl Med Biol 15: 231-233, 1988.
70. DeNardo SJ, DeNardo GL, Deshpande SV, Adams GP, Macey DJ, Mills SL, Epstein AL, Meares CF: The design of a radiolabeled monoclonal antibody for radioimmunodiagnosis and radioimmunotherapy. In; Radiolabeled Monoclonal Antibodies for Imaging and Therapy (Srivastava, SC, ed). New York, Plenum Publishing Corp. 1988, pp 111-122.